Pyrilutamide

Pyrilutamide, also known by its development code KX-826, is a nonsteroidal androgen receptor (AR) antagonist developed as a topical treatment for androgenetic alopecia (male and female pattern hair loss) and studied for acne ^[1][2]. It was created by the biopharmaceutical company Kintor Pharmaceutical and belongs to the same broad class of AR-blocking drugs as the antiandrogens used in prostate cancer, but it is formulated for application to the skin so that it acts locally rather than systemically ^[2][3]. In medicinal-chemistry terms it is built on a thiohydantoin scaffold, the chemical framework shared by modern AR antagonists, and it has become a benchmark compound against which newer topical AR antagonists are compared ^[3].

The rationale for pyrilutamide rests on the biology of pattern hair loss. In androgenetic alopecia, the androgen dihydrotestosterone (DHT) binds the androgen receptor in genetically susceptible scalp hair follicles, driving progressive follicular miniaturization, a shortened growth (anagen) phase, and thinning hair; blocking the receptor interrupts this cascade ^[4]. Existing systemic therapies that lower or block androgens, such as the 5-alpha-reductase inhibitor finasteride, are effective but carry a well-publicized risk of sexual and other systemic side effects, which has driven demand for treatments that act only where they are applied ^[5][6]. Pyrilutamide is designed to occupy the androgen receptor in the skin of the scalp, reducing DHT signaling in the follicle without meaningfully suppressing hormones in the rest of the body ^[1][2].

Pyrilutamide is an investigational drug and has not been approved by the United States Food and Drug Administration or, as of this writing, brought to market as a finished medicine in Western countries; it has been evaluated in clinical trials, and reviews describe it as a promising but still-unproven pipeline agent whose results have been mixed and require larger, standardized studies to confirm ^[1][2]. It is nonetheless widely sold through the research-chemical and cosmetic-supply market as a topical solution, where product quality and concentration are not guaranteed ^[2][3]. It is typically encountered as a dissolved topical solution applied to the scalp ^[3].

Pyrilutamide (KX-826) is an investigational topical androgen receptor antagonist for hair loss that has not received regulatory approval, so its long-term safety is not established. Adverse effects reported in trials have been mainly local, such as scalp irritation, itching, and contact dermatitis. Because it blocks androgen receptors, systemic antiandrogenic effects cannot be entirely excluded, although measured systemic absorption appears low.

Pyrilutamide, known by its development code KX-826, is an investigational topical androgen receptor antagonist developed by the Chinese biopharmaceutical company Kintor Pharmaceutical for androgenetic alopecia and acne. It emerged from the broader effort to design nonsteroidal antiandrogens that could be applied directly to the skin, blocking dihydrotestosterone at the hair follicle while minimizing the systemic hormonal exposure associated with oral agents such as finasteride. In preclinical hair-growth models the compound demonstrated measurable regrowth and became a reference standard against which newer topical androgen receptor antagonists are compared in the medicinal chemistry literature.

It subsequently advanced into human clinical trials for pattern hair loss, positioning it as one of the most closely watched investigational treatments in the field. Independent reviews of emerging hair-loss therapies published as recently as 2026 continue to describe KX-826 as offering targeted androgen receptor modulation without systemic hormonal suppression, while cautioning that heterogeneity in trial design and endpoints means its true efficacy in people remains to be firmly established. As an experimental agent, it has not received general regulatory approval.

Pyrilutamide has generated considerable excitement as a next-generation approach to pattern hair loss, precisely because it aims to solve the problem that deters many people from oral treatments: unwanted systemic hormonal effects. By blocking the androgen receptor locally in the scalp rather than lowering DHT throughout the body, it holds out the appealing prospect of protecting follicles without the sexual or mood side effects sometimes reported with finasteride.

Its strong performance in preclinical models has made it a benchmark that other topical antiandrogens are measured against, and recent expert reviews highlight it as a leading investigational option. Candor is essential here: it remains experimental, human trial results have been mixed, and reviewers stress that larger, rigorous, long-term studies are still needed before its real-world efficacy and safety can be considered established. For now it is best understood as a genuinely promising but still-unproven frontier therapy.